Loading...
•
Sep 30, 2021
Delcath Q3 2021 Earnings Report
Delcath's financial performance and business highlights were reported for Q3 2021.
Key Takeaways
Delcath Systems reported product revenue of $522 thousand for the three months ended September 30, 2021, compared to $466 thousand for the prior year period. The company's net loss for the quarter was $7.1 million, compared to a net loss of $5.0 million for the same period in 2020. They closed a $20 million venture debt financing transaction with Avenue Venture Opportunities Fund, L.P. during the quarter.
Product revenue increased to $522 thousand compared to $466 thousand in the prior year period.
Net loss was $7.1 million, compared to $5.0 million for the same period in 2020.
Avenue Venture Opportunities Fund, L.P. provided up to $20 million with an initial $15 million funded at closing.
FDA approved an expanded access protocol for the use of HEPZATO in treating liver dominant metastatic ocular melanoma.
Forward Guidance
Delcath is focused on filing the HEPZATO NDA in mid-2022, preparing for the subsequent US launch, and expanding the development of HEPZATO into additional areas.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...